Optimal dose and duration of heparin for inhibition of intimal hyperplasia

International Angiology

Volumn 16, Issue 2, 1997, Pages 94-100

  Ao, P Y ^a   Hawthorne, W J ^a   Taylor, D A ^a   Fletcher, J P ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Blood vessel prosthesis; Heparin, therapeutic use; Hyperplasia, prevention and control; Tunica intima pathology

Indexed keywords

DACRON; HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL PROSTHESIS; COMMON CAROTID ARTERY; CONTROLLED STUDY; DACRON IMPLANT; MICROSCOPY; NONHUMAN; SHEEP; SUBCUTANEOUS DRUG ADMINISTRATION; THICKNESS; TIME;

ANIMALS; BLOOD VESSEL PROSTHESIS; CAROTID ARTERY, COMMON; DRUG ADMINISTRATION SCHEDULE; HEPARIN; HYPERPLASIA; POLYETHYLENE TEREPHTHALATES; SHEEP; TIME FACTORS; TUNICA INTIMA;

EID: 0030797249     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Szilagyi DE, Smith RF, Elliott JP, Allen HM. Long-term behaviour of a Dacron arterial substitute. Clinical, roentgenologic and histologic correlation. Ann Surg 1965;162:453-77.
2. Kent KC, Whittemore AD, Mannick JA. Short-term and midterm results of an all-autogenous tissue policy for infrainguinal reconstruction. J Vasc Surg 1989;9:107-14.
3. Walker PJ, Mitchell RS, McFadden PM, James DR, Mehigan JT. Early experience with cryopreserved saphenous vein allografts as a conduit for complex limbsavage procedures. J Vasc Surg 1993;18:561-9.
4. Becquemin JP, Haiduc F, Cavillon A. Thrombogenicity of an elastomer-coated aortofemoral Dacron prosthetic graft in humans. Ann Vasc Surg 1994;8(5):443-51.
5. Echave V, Koornick AR, Haimov M, Jacobson JH. Intimai hyperplasia as a complication of the use of the polytetrafluoroethylene grafts for femoral-popliteal bypass. Surgery 1979;86:791-8.
6. Imparato AM, Bracco A, Kim GE, Zeff R. Intimai and neointimal fibrous proliferation causing failure of arterial reconstructions. Surgery 1972;72:1007-17.
7. Clowes AW, Cown AM, Hanson SR, Reidy MA. Mechanisms of arterial graft failure: I, Role of cellular proliferation in early healing of PTFE prostheses. Am J Pathol 1985;118:43-54.
8. Chervu A, Moore WS. An overview of intimai hyper-plasia. Surg Gynaecol Obstet 1990;171:433-46.
9. Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977;265:625-6.
10. Majesky MW, Schwartz SM, Clowes MM, Clowes AW. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ Res 1987;61:296-300.
11. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury IV. Heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res 1986;58:839-45.
12. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia. A review. Vasc Surg 1991;13:885-90.
13. Chan P, Mill S, Mulloy B, Kakkar V, Demoliou-Mason C. Heparin inhibition of human vascular smooth muscle cell hyperplasia. Int Angiol 1992;11:261-7.
14. Taylor DA, Ao PY, Fletcher JP. Inhibition of intimai hyperplasia and occlusion in Dacron graft with heparin and low molecular weight heparin. Int Angiol, in press.
15. Clowes AW, Clowes MM, Vergel SC, Muller RKM, Pwell JS, Hefti F et al. Heparin and cilazapril together inhibit injury-induced intimal hyperplasia. Hypertension 1991;18(Suppl II):65-9.
16. Mant MJ, O'Brien BD, Thong KL, Hammond GW, Birtwhistle RU, Grace MG. Haemorrhagic complication of heparin therapy. Lancet 1977;1:1133.
17. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute thromboembolism with heparin or low molecular weight heparin. Blood 1991;78:2337-43.
18. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-33.
19. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985;56:139-45.
20. Clowes AW, Reidy MA, Clowes MM. Mechanism of stenosis after arterial injury. Lab Invest 1983;49:208-15.
21. Radhakrishnamurthy B, Ruiz HA, Berenson GS. Isolation and characterization of proteoglycans from bovine aorta. J Biol Chem 1977;252:4831-41.
22. Castellot JJ, Addowizio ML, Rosenberg RD, Karnovsky MJ. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Biol 1981;90:372-9.
23. Majack RA, Clowes AW. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol 1984;118:253-6.
24. Fritze LM, Reilly CF, Rosenberg RD. An antiproliferative heparin sulfate species produced by postconfluent smooth muscle cells. J Cell Biol 1985;100:1041-9.
25. Hoover RL, Rosenberg R, Haering W, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies. Circ Res 1980;47:578-83.
26. Guyton JR, Rosenberg RD, Clowes AW, Karanorsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo study with anticoagulant and non-anticoagulant heparin. Circ Res 1980;46:625-34.
27. Castellor JJ, Cochran DL, Karnorsky MJ. Effect of heparin on vascular smooth muscle cells II. Cell metabolism. J Cell Physiol 1985;124:21-8.
28. Reilly CF, Fritze LM, Rosenberg RD. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol 1986;129:11-9.
29. Mjack RA, Bornstein P. Heparin and related glycosaminoglycans modulate the secretory phenotype of vascular smooth muscle cells. J Cell Biol 1984;99: 1688-95.
30. Snow DA, Bolender RP, Wight TN, Clowes AW. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol 1990;137:313-30.
31. Hansson GK, Jonasson L, Holm J, Cloves MM, Clowes AW. Gamma interferon regulates vascular smooth muscle proliferation and Ia expression in vitro and in vivo. Circ Res 1988;63:712-9.
32. Norman PG, House AK. Heparin reduces the intimai hyperplasia seen in microvascular vein grafts. Aust N Z J Surg 1991;61:942-8.
33. Wison NV, Salisbury JR, Kakkar VV. Effect of low molecular weight heparin on intimai hyperplasia. Br Surg 1991;78:1381-3.
34. Donayre CE, Ourid K, Rhee RY, Shortell CK. Future alternatives to heparin: Low-molecular-weight heparin and hirudin. J Vasc Surg 1992;15:675-82.
35. Swhwartz RS, Holder DJ, Holmes DR. Neointimal thickening after severe coronary artery injury is limited by a short-term administration of factor Xa inhibitor. Results in a porcine model. Circ 1996;93: 1542-8.